Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment

Louise A. Donnelly, Natalie R. van Zuydam, Kaixin Zhou, Roger Tavendale, Fiona Carr, Anke H. Maitland-van der Zee, Maarten Leusink, Anthonius de Boer, Pieter A. Doevendans, Folkert W. Asselbergs, Andrew D. Morris, Ewan R. Pearson, Olaf H. Klungel, Alex S. F. Doney, Colin N. A. Palmer

    Research output: Contribution to journalArticlepeer-review

    20 Citations (Scopus)

    Abstract

    The LPA single-nucleotide polymorphism rs10455872 has been associated with low-density lipoprotein cholesterol (LDLc) lowering response to statins in several randomized control trials (RCTs) and is a known coronary artery disease (CAD) marker. However, it is unclear what residual risk of CAD this marker may have during statin treatment.
    Original languageEnglish
    Pages (from-to)518-525
    Number of pages8
    JournalPharmacogenetics and Genomics
    Volume23
    Issue number10
    Early online date30 Jul 2013
    DOIs
    Publication statusPublished - 2013

    Fingerprint Dive into the research topics of 'Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment'. Together they form a unique fingerprint.

    Cite this